Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-center, Single-arm, Phase II Study of QL1706 Combined with Nine价HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

NCT06882447 is registered in ClinicalTrials.gov with Northern Jiangsu People's Hospital as lead sponsor.

NCT NCT06882447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06882447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-center, Single-arm, Phase II Study of QL1706 Combined with Nine价HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
Lead sponsor
Northern Jiangsu People's Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2025
Completion date
December 31, 2028
Enrollment
35 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer stage ivb